
Amphastar Pharmaceuticals, Inc.
AMPHNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$21.59
−$0.08 · -0.37%
AMPH company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
83
Deep Value
Momentum
26
Weakening
Sentiment
64
Bullish
Risk resilience
43
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAmphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Yongfeng Zhang
- Listed since
- Jun 25, 2014
- Employees
- 1,976
Market position
- Volume
- 376.56K
- 0.67× average
- Average volume
- 564.79K
- Average daily volume
- Market cap
- 952.41M USD
- Beta
- 0.9
- Market reference 1
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- +4.85%
- 11 comparable reports
- Latest EPS result
- 0.91
- Estimate 0.62 · Beat by 46.77%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
12 ratingsRecent analyst actions
AMPH peers
Continue in GoAI
Research AMPHresearch.disclaimer





